Unternehmensübersicht
Chiron Real Estate Inc. operates as a specialized net-lease medical real estate investment trust focused on the healthcare infrastructure sector. The company acquires medical facilities and leases them under net-lease agreements to physician groups as well as regional and national healthcare systems, thereby generating stable rental income streams. Incorporated in 2011 within the state of Maryland, USA, the entity functions within the REIT - Healthcare Facilities industry classification. The firm currently maintains a market capitalization of $879.56M and employs approximately 30 staff members to support its operations. With an annual revenue of $148.06M, the company's financial scale reflects a mid-to-large cap position within the specialized healthcare real estate niche, indicating significant asset ownership relative to its workforce size.
Finanzielle Gesundheit
The company reported a trailing twelve-month revenue of $148.06M, yet recorded a net income of -$12,116,000, revealing a substantial discrepancy between top-line growth and bottom-line profitability. This negative net income despite positive revenue suggests high operating expenses or significant non-operating charges that erode the earnings generated from facility leases. Conversely, the entity reported an EBITDA of $91.58M, highlighting strong operational cash generation before interest, taxes, depreciation, and amortization. Free cash flow stands at $66.62M, which demonstrates that the business generates sufficient liquidity to cover capital expenditures and debt obligations without relying on external financing. The gross margin is listed at 100.0%, indicating that the primary cost of goods sold is immaterial compared to revenue in this asset-heavy model. However, the operating margin sits at 25.1% while the profit margin is negative at -3.9%, illustrating how interest and other expenses impact the final profitability picture. On the liquidity front, total cash holdings of $15.19M are significantly lower than the total debt load of $667.29M. The debt-to-equity ratio of 125.89 confirms that the balance sheet is highly leveraged, relying heavily on borrowed capital to finance its real estate portfolio. Despite the high leverage, the current ratio of 1.75 indicates that the company possesses adequate short-term assets to cover its current liabilities. Return on equity is negative at -1.3%, while return on assets remains positive at 1.9%, suggesting that management is utilizing assets to generate income before financing costs, but the high cost of debt is suppressing equity returns.
Bewertungsanalyse
The valuation metrics present a complex picture, with a trailing P/E ratio marked as N/A due to the recent net losses, while the forward P/E is listed at -53.39. The negative forward P/E implies that analysts or market participants expect earnings to remain negative or are pricing in a future where losses persist under current projections. The price-to-book ratio is 1.11, suggesting that the market values the company slightly above its tangible book value, which is typical for real estate firms where asset values may differ from accounting book values. Alternative valuation multiples provide further context; the price-to-sales ratio is 5.94, indicating a premium valuation relative to revenue, while the EV/EBITDA stands at 13.37. Regarding trading range, the 52-week high is $44.40 and the 52-week low is $29.05. Without a specific current share price provided in the source data, the precise percentage distance from the high or low cannot be calculated, but the spread indicates a trading range of $15.35. The stock exhibits a beta of 1.21, meaning its price volatility is 21% higher than the broader market benchmark. This elevated beta suggests that the share price is more sensitive to market swings than the average stock, reflecting the inherent risks associated with the healthcare real estate sector.
Growth & Income
Revenue growth year-over-year is recorded at 9.2%, demonstrating consistent top-line expansion likely driven by lease renewals or new acquisitions. Earnings growth is listed as N/A, which implies that the company has not yet achieved consistent positive earnings growth to calculate a meaningful year-over-year percentage. The divergence between positive revenue growth and negative earnings growth indicates that top-line gains are currently being consumed by fixed costs or interest expenses rather than translating into net profit. As a dividend payer, the company offers a dividend yield of 9.3%, but the payout ratio is excessively high at 1114.3%. This payout ratio is not sustainable based on current net income, as the company would need to distribute more dividends than its reported earnings, likely relying on cash flow or asset sales to fund these distributions. The high yield therefore reflects the depressed share price rather than a commitment to pay dividends out of current profits. The overall growth and income profile is characterized by strong revenue expansion and a high-yield dividend supported by robust free cash flow, albeit with significant leverage and negative reported net income.